Scholarlink

<p>Chimeric antigen receptor (CAR) T-cell immunotherapy has achieved clinical success, but remains limited in solid tumors by antigen escape and tumor heterogeneity. Here, we engineer a high-affinity R-phycoerythrin (PE)-binding monobody to create a PE-programmable CAR toward user-defined antigens sequentially or simultaneously. To reduce off-tumor toxicity, we implement a drug-gated light-activation approach (DGLA) strategy to spatially confine CAR function. We further couple DGLA-controlled tumor antigen presentation with synNotch-mediated programmable antigen-targeting CAR (sPAT) to establish programmable CAR-antigen pairing (DGLA-sPAT). This system induces clinically validated antigens on tumor cells as local ‘training centers’ that recruit and activate sPAT CAR T cells, enabling elimination of entire tumor populations through broadly expressed tumor antigens using PE-conjugated antibodies. In vivo, DGLA-sPAT manifests local T cell activation and potent tumor suppression with minimal off-tumor toxicity. Thus DGLA-sPAT provides a modular and spatially controlled framework to overcome antigen escape and heterogeneity while improving safety in solid-tumor CAR-T therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Engineering programmable CAR and antigen pairing via drug-gated light activation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月19日

查看全文
  • Ziliang Huang,
  • Praopim Limsakul,
  • Yiqian Wu,
  • Tianze Guo,
  • Yuxuan Wang,
  • Zhuohang Wu,
  • Linshan Zhu,
  • Molly E. Allen,
  • Longwei Liu,
  • Yingxiao Wang

摘要

Chimeric antigen receptor (CAR) T-cell immunotherapy has achieved clinical success, but remains limited in solid tumors by antigen escape and tumor heterogeneity. Here, we engineer a high-affinity R-phycoerythrin (PE)-binding monobody to create a PE-programmable CAR toward user-defined antigens sequentially or simultaneously. To reduce off-tumor toxicity, we implement a drug-gated light-activation approach (DGLA) strategy to spatially confine CAR function. We further couple DGLA-controlled tumor antigen presentation with synNotch-mediated programmable antigen-targeting CAR (sPAT) to establish programmable CAR-antigen pairing (DGLA-sPAT). This system induces clinically validated antigens on tumor cells as local ‘training centers’ that recruit and activate sPAT CAR T cells, enabling elimination of entire tumor populations through broadly expressed tumor antigens using PE-conjugated antibodies. In vivo, DGLA-sPAT manifests local T cell activation and potent tumor suppression with minimal off-tumor toxicity. Thus DGLA-sPAT provides a modular and spatially controlled framework to overcome antigen escape and heterogeneity while improving safety in solid-tumor CAR-T therapy.